The Low Incidence of Secondary Acute Myelogenous Leukemia in Children and Adolescents Treated with Dexrazoxane for Acute Lymphoblastic Leukemia: A Report from the Dana-Farber Cancer Institute ALL Consortium

BACKGROUND: Dexrazoxane reduces the risk of anthracycline-related cardiotoxicity. In a study of children with Hodgkin lymphoma, the addition of dexrazoxane may have been associated with a higher risk for developing second malignant neoplasms (SMNs) including acute myelogenous leukemia (AML) and myel...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Vrooman, Lynda M., Neuberg, Donna S., Stevenson, Kristen E., Asselin, Barbara L., Athale, Uma H., Clavell, Luis, Cole, Peter D., Kelly, Kara M., Larsen, Eric C., Laverdière, Caroline, Michon, Bruno, Schorin, Marshall, Schwartz, Cindy L., Cohen, Harvey J., Lipshultz, Steven E., Silverman, Lewis B., Sallan, Stephen E.
Format: Artigo
Langue:Inglês
Publié: 2011
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3736806/
https://ncbi.nlm.nih.gov/pubmed/21514146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2011.03.022
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires